SynBioBeta Speaker
Susan Klaeger
Genentech
Principal Scientist
Dr. Susan Klaeger is a Principal Scientist and Group Lead of Immunopeptidomics and Surface Proteomics at Genentech, a role she has held since 2022. Her research is focused on applied proteomics, specializing in immunopeptidomics and proteogenomics to discover and validate novel cancer antigens and biomarkers for therapeutic development. She holds a PhD from the Technical University of Munich and the German Cancer Consortium, where she applied chemoproteomics approaches to study selectivity of clinical kinase inhibitors, followed by a postdoctoral fellowship at The Broad Institute of MIT and Harvard, where her research focused on improving detection of MHC presented peptides, generation of large scale datasets for AI/ML approaches and proteogenomic integration to the discovery of MHC presented peptides derived from novel, unannotated open reading frames.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Susan
This Year
•
-
AIxBIO
The Dark Proteome: Why Protein Sequencing Is Science's Next Frontier
Billions of proteins remain uncharacterized - invisible to current tools, unknown in function, and untapped in potential. This fireside chat explores why protein sequencing is poised to become the defining technology of the next decade in biology, what "protein dark matter" really means for drug discovery and synthetic biology, and how the field is building the infrastructure to illuminate what genomics left in the shadows.
Get a Ticket
Featuring
Sue Siegel
Align & Illumina
Board Director
Top 100 Most Influential Women in Silicon Valley. Health-tech rainmaker who built GE’s venture engine.
Leroy Hood
ISB
Co-founder and Professor
Jennifer Dionne
Stanford University
Professor
Susan Klaeger
Genentech
Principal Scientist
Michael Koeris
DARPA
Director, BTO
Protecting National Security with Biology
•
-
AIxBIO
The Dark Proteome: Why Protein Sequencing Is Science's Next Frontier
Billions of proteins remain uncharacterized - invisible to current tools, unknown in function, and untapped in potential. This fireside chat explores why protein sequencing is poised to become the defining technology of the next decade in biology, what "protein dark matter" really means for drug discovery and synthetic biology, and how the field is building the infrastructure to illuminate what genomics left in the shadows.
Get a Ticket
Featuring
Sue Siegel
Align & Illumina
Board Director
Top 100 Most Influential Women in Silicon Valley. Health-tech rainmaker who built GE’s venture engine.
Leroy Hood
ISB
Co-founder and Professor
Jennifer Dionne
Stanford University
Professor
Susan Klaeger
Genentech
Principal Scientist
Michael Koeris
DARPA
Director, BTO
Protecting National Security with Biology
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
